Table 6.

AKT inhibitors in phase III clinical trials ¹.

Inhibitor	Target	Condition or Disease	ClinicalTrials.gov Identifier
Ipatasertib and Paclitaxel	AKT and microtubules	Locally advanced or metastatic TNBC; locally advanced or metastatic HR+/HER2– breast adenocarcinoma	NCT03337724 Study start date: January 2018 Estimated study completion date: December 2021
Ipatasertib and Abiraterone	AKT and CYP17	Metastatic castrate-resistant prostate cancer	NCT03072238 Study start date: June 2017 Estimated study completion date: November 2023
Ipatasertib, Palbociclib, and Fulvestrant	AKT, CDK4/6, and ER	HR+ and HER2– locally advanced unresectable or metastatic breast cancer	NCT04060862 Study start date: November 2019 Estimated study completion date: January 2026
Ipatasertib, Paclitaxel, and Atezolizumab	AKT, microtubules, and PD-L1	Locally advanced or metastatic TNBC	NCT04177108 Study start date: November 2019 Estimated study completion date: October 2025
Ipatasertib and Fulvestrant	AKT and ER	Advanced HER2– and ER+ breast cancer	NCT04650581 Estimated study start date: December 2020 Estimated study completion date: December 2026
Capivasertib and Paclitaxel	AKT and microtubules	Locally advanced or metastatic TNBC	NCT03997123 Study start date: June 2019 Estimated study completion date: January 2023
Capivasertib and Abiraterone	AKT and CYP17	Hormone-sensitive prostate cancer	NCT04493853 Study start date: July 2020 Estimated study completion date: November 2025
Capivasertib and Fulvestrant	AKT and ER	Locally advanced (inoperable) or metastatic HR+/HER2– breast cancer	NCT04305496 Study start date: April 2020 Estimated study completion date: July 2024

¹ Clinical trial data obtained from https://clinicaltrials.gov at 25 December 2020. CDK, cyclin-dependent kinase; HER2–, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive; ER+, estrogen receptor positive; TNBC, triple-negative breast cancer.